Potential Diagnostic and Prognostic Value of Plasma Circulating MicroRNA-182 in Human Glioma

Abstract

BackgroundPrevious studies showed the aberrant expression of microRNA-182 (miR-182) in glioma tissue. However, the exact role of circulating miR-182 in glioma remains unclear. Here, we confirmed the expression of plasma circulating miR-182 in glioma patients, and further explored its potential diagnostic and prognostic value.Material/MethodsReal-time quantitative PCR (RT-PCR) was used to measure circulating cell-free miR-182 from 112 glioma patients and 54 healthy controls.ResultsOur findings showed that the level of circulating miR-182 in glioma patients was higher than that in healthy controls (P<0.001), which was significantly associated with KPS score (P=0.025) and WHO grade (P<0.001). The area under the receiver operating characteristic (ROC) curve (AUC) was 0.778. The optimal cut-off value was 1.56, and the sensitivity and specificity were 58.5% and 85.2%, respectively. Interestingly, a high predictive value of circulating miR-182 was observed in high-grade glioma (AUC=0.815). However, the AUC was lower in low-grade glioma (AUC=0.621). Kaplan-Meier analysis demonstrated that the cumulative 5-year overall survival rate in the high miR-182 group was significantly lower than that in the low miR-182 group in both overall survival (OS) (P=0.003) and disease-free survival (DFS) (P=0.006). Moreover, multivariate Cox analysis revealed that circulating miR-182 was an independent prognostic indicator for OS (P=0.034) and DFS (P=0.013).ConclusionsThese results suggest that circulating miR-182 may be a potential noninvasive biomarker for the diagnosis and prognosis of human glioma.

Serum microRNA profiling in patients with glioblastoma: a survival analysis

“…Knockdown of either miR-20a or miR-106a was observed to increase TIMP-2 expression and consequently inhibit glioma stem cell invasion. Xiao et al found that high levels of plasma miR-182 were associated with poor overall survival ( P  = 0.034) and disease-free survival ( P  = 0.013) among glioma patients [24]. However, in our study, we found that decreased levels of miR-182 were associated with poor overall survival ( P  = 0.037) and disease-free survival ( P  = 0.043) among glioblastoma patients.…”

Micro RNA Molecules as Modulators of Treatment Resistance, Immune Checkpoints Controllers and Sensitive Biomarkers in Glioblastoma Multiforme

“…The existence of similar correlations has been demonstrated by many other researchers, including: miR19, miR137, miR144-3p, and miR182 [98][99][100][101]. It was also found that the relationship between the stage of tumor histology is positive for miR19 and miR182, and negative for le7e, miR145 and miR181a [102,103]. This would provide valuable guidance on the characteristics of the tumor before surgery and histopathological examination of the slice, giving the chance for better planning of the procedure.…”

MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta‐analysis

“…Subsequently, we assessed the remaining 254 full‐text articles and excluded 226 studies based on the exclusion criteria, including 30 meetings, and 196 without clinical data to make a 2 × 2 contingency table. In total, 28 studies were ultimately included in this study . A flowchart of the selection process for this study is presented in Figure .…”